The HBA1 Knockout HeLa Polyclonal Cells are a precisely engineered CRISPR/Cas9-edited polyclonal cell population derived from the HeLa human cervical adenocarcinoma epithelial cell line (Homo sapiens). This product features targeted disruption of the HBA1 gene, which encodes alpha-globin, the critical oxygen-binding subunit of hemoglobin A and a component with emerging non-erythroid functions. The polyclonal format provides a heterogeneous knockout population suitable for studies that do not require clonal isolation, offering a practical loss-of-function model for investigating alpha-globin biology in a widely used cancer cell background.
The parental HeLa cell line is an immortalized cervical cancer epithelial model originating from a cervical adenocarcinoma and stably carries integrated human papillomavirus type 18 (HPV18) DNA. The consequent expression of the viral oncoproteins E6 and E7 inactivates the tumor suppressors p53 and Rb, respectively, driving sustained proliferation and genomic instability. These characteristics have established HeLa cells as a versatile and extensively characterized platform for studying cancer cell biology, signal transduction, and host?Cpathogen interactions.
Alpha-globin, encoded by HBA1, assembles with beta-globin (HBB) and heme to form hemoglobin A, the major oxygen carrier, and additionally engages in nitric oxide (NO) metabolism by interacting with endothelial nitric oxide synthase (eNOS) and scavenging NO. Transcription of HBA1 is regulated by GATA1, NF-E2, and KLF1 downstream of erythropoietin and hypoxic signals, while the chaperone alpha-hemoglobin stabilizing protein (AHSP) maintains alpha-globin stability. Loss of HBA1 disrupts heme homeostasis, reactive oxygen species (ROS) balance, and NO signaling.
In HeLa cells, HBA1 knockout abrogates alpha-globin expression, which is expected to perturb intracellular heme trafficking and alter the cellular redox environment by reducing heme-buffering capacity. Loss of alpha-globin may compromise NO scavenging and interfere with eNOS-mediated signaling, potentially modifying the cancer cell??s response to nitrosative stress. Furthermore, because HeLa cells rely on altered metabolic pathways to support rapid growth, the removal of alpha-globin provides a unique model to examine how heme and globin proteins intersect with cancer metabolism, apoptosis, and oxidative stress resistance in a non-erythroid context.
This polyclonal knockout cell pool supports a broad range of experimental investigations, including functional assays for non-erythroid alpha-globin, heme trafficking and ROS detection studies, and modeling of alpha-thalassemia-related cellular phenotypes. Researchers can employ Western blotting and RT-qPCR to confirm HBA1 disruption, heme measurement and ROS probes to assess metabolic changes, and NO bioavailability assays to evaluate vasoregulatory interactions. Transcriptomic profiling via RNA-seq and flow cytometric analysis of oxidative stress markers further expand the utility of these cells for pathway discovery and drug screening. For additional details, protocols, or custom inquiries, please contact Ascent Research.
